A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Portugal- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Portugal489 clinical trials in Porto, Portugal across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
PortugalThe busiest research cities in the country
What the registry says about research in the country
Innovative research focusing on polypoidal choroidal vasculopathy and rare genetic conditions like PMM2-CDG, exploring new treatment approaches to improve patient outcomes.
Groundbreaking studies in chronic myelogenous leukemia, multiple myeloma, and advanced malignancies, including research on novel therapies for non-small cell lung cancer.
Comprehensive research into conditions like hidradenitis suppurativa, plaque psoriasis, and pyoderma gangrenosum, evaluating new therapeutic approaches.
Studies examining hypertrophic cardiomyopathy, familial hypercholesterolemia, and innovative treatments for obesity.
Investigating treatments for Dravet Syndrome, menstrual migraine, and rare conditions like Niemann-Pick disease.
Tell us about your condition – we search every trial in Europe and connect you with the right site.